Skip to content

Effect of blood derivatives in preserving and enhancing tooth extraction sockets for prosthetic rehabilitation

Effect of lyophilized platelet-rich fibrin matrix (PRFM) in tooth extraction socket to foster alveolar ridge preservation for dental prosthetic rehabilitation - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055690
Enrollment
70
Registered
2023-07-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K069- Disorder of gingiva and edentulousalveolar ridge, unspecified

Interventions

Intervention1: Lyophilized Platelet Rich Fibrin Matrix: The extraction socket/sockets will be treated immediately by the placement of lyophilized PRFM and compressed by pressure application. The numbe

Sponsors

Dr Anil Mathew
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals within an age limit of 18 â?? 65 years for implant treatment 2. Patients committed to the study and willing to sign the informed consent 3. Healthy patients with an indication for dental extraction without other restorative treatment possibilities provided that the socket walls are intact. 4. Patients who require prosthetic rehabilitation necessarily with an implant-supported prosthesis after extraction. 5. Patients indicated for implant treatment should be functionally dentulous with minimum of 20 teeth with 9to 10 pairs of contacting teeth and the proposed extraction site should be tooth bound and with opposing natural teeth or fixed restoration Tooth numbers below a minimum of 20 teeth, with nine to 10 pairs of contacting units, are associated with impaired masticatory efficiency, performance, and masticatory ability 6. Patients who are willing for withdrawal of blood and socket reconstruction. 7. Individuals who are willing to report at the required intervals for evaluation.

Exclusion criteria

Exclusion criteria: The participant may not enter the trial if ANY of the following apply: 1. History of infectious diseases, bleeding disorder, or on medications that impair platelet function such as anticoagulant therapy. 2. Patients on aspirin, history of cardiac problems (congenital/acquired heart disease, cerebrovascular accidents, or valvular disease) or undergone cardiac surgeries (coronary bypass surgery, valvular prosthesis surgeries). 3. Individuals with known systemic risk factors for impaired wound healing, such as uncontrolled hypertension, uncontrolled diabetes, and bone metabolic diseases. (BP >180/110 mm HG will be considered uncontrolled hypertension as it is contraindicated for implant causing impaired blood supply and the consequent hypoxia may negatively affect the healing process of bone around implants. HbA1C > 8.1% will be considered uncontrolled diabetes as it cause a delay in integration and implant stability). 4.Severe periodontal disease, as patients with poor bone quality, severe alveolar bone resorption, and alveolar bone defects in tooth extraction sites or with acute periapical pathology 5.Patients with removable prosthesis occluding or opposite to proposed extraction site planned for implant placement and who are functionally edentulous. 6.Severely damaged extraction socket with more than 2 bone wall defect and hard tissue loss of more than 5mm (based on Extraction Defect Sounding Classification(EDS) evaluated by the tip of periodontal probe) 7.Pregnant patients/breastfeeding mothers ( Radiation dose of CBCT pose risk to the fetus and high anxiety levels in an expectant mother during elective surgery can affect the development of a baby. Antibiotic therapy and NSAIDs after surgery might not be safe for breast milk and newborns.). 8.Patients undergoing bisphosphonates therapy, exposure to head and neck radiation/ chemotherapy, or who are immune-compromised. 9. A habit of smoking > 10 cigarettes/day or use of tobacco (More than 10 cigarettes has a significant correlation to implant failure. Cytotoxicity of nicotine to the cells involved in wound healing, vasoconstriction, and increased platelet adhesiveness and blood viscosity leading to the risk of microvascular occlusion, increases marginal bone loss). 10.A habit of para-function like severe bruxism (as it is a relative contraindication to implant prosthesis leading to failure). 11.Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participantâ??s ability to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Assessment of alveolar ridge volume and dimensions and implant outcomeTimepoint: Baseline, 3 months, 6 months, 18 months

Secondary

MeasureTime frame
Post Operative Pain AnalysisTimepoint: 24 hours, 3 days, 7 days;Prosthesis outcomeTimepoint: one year after prosthetic rehabilitation;Soft tissue healingTimepoint: 1 day, 3 days, 7 days, and 3 months after extraction and PRF intervention

Countries

India

Contacts

Public ContactDr Chandrashekar Janakiram

Amrita VishwaVidyapeetham

dr.anilmathew@yahoo.com9447040045

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026